TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
+46.64%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$960M
AUM Growth
+$960M
(-11%)
Cap. Flow
-$331M
Cap. Flow
% of AUM
-34.51%
Top 10 Holdings %
Top 10 Hldgs %
38.43%
Holding
146
New
23
Increased
17
Reduced
40
Closed
47
Top Buys
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$24.5M |
| 2 |
Outlook Therapeutics
OTLK
|
$19.3M |
| 3 |
Immunome
IMNM
|
$17.8M |
| 4 |
Applied Therapeutics
APLT
|
$15.2M |
| 5 |
Evolus
EOLS
|
$14.7M |
Top Sells
Sector Composition
| 1 | Healthcare | 98.03% |
| 2 | Technology | 0.94% |
| 3 | Communication Services | 0.51% |
| 4 | Real Estate | 0.32% |
| 5 | Financials | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Verastem
VSTM
$585M
| $6.39M | 0.67% |
541,514
-200,000
| -27% | -$2.36M |
|
52
Design Therapeutics
DSGN
$339M
| $5.97M | 0.62% |
1,480,975
+300
| +0% | +$1.21K |
|
53
Nkarta
NKTX
$149M
| $5.95M | 0.62% |
550,000
| – | – |
|
|
ONC
54
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.5B
| $5.79M | 0.6% |
37,000
-48,000
| -56% | -$7.51M |
|
55
Intellia Therapeutics
NTLA
$1.26B
| $5.5M | 0.57% |
200,000
| – | – |
|
56
Enanta Pharmaceuticals
ENTA
$189M
| $5.24M | 0.55% |
300,000
| – | – |
|
57
Fate Therapeutics
FATE
$119M
| $5.14M | 0.54% |
700,000
| – | – |
|
58
Heron Therapeutics
HRTX
$204M
| $5.12M | 0.53% |
1,850,000
| – | – |
|
59
BioAtla
BCAB
$28.7M
| $5.07M | 0.53% |
1,474,076
-1,050,000
| -42% | -$3.61M |
|
|
OKUR
60
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$38.3M
| $4.98M | 0.52% |
299,700
-33,300
| -10% | -$553K |
|
61
Meta Platforms (Facebook)
META
$1.85T
| $4.86M | 0.51% |
+10,000
| New | +$4.86M |
|
62
Bolt Biotherapeutics
BOLT
$9.29M
| $4.79M | 0.5% |
171,000
-11,612
| -6% | -$325K |
|
63
Structure Therapeutics
GPCR
$1.14B
| $4.29M | 0.45% |
+100,000
| New | +$4.29M |
|
64
BioCryst Pharmaceuticals
BCRX
$1.74B
| $4.06M | 0.42% |
800,000
| – | – |
|
65
Century Therapeutics
IPSC
$40.4M
| $3.76M | 0.39% |
900,000
-166,440
| -16% | -$696K |
|
|
BLUE
66
DELISTED
bluebird bio
BLUE
| $3.2M | 0.33% |
125,000
+40,000
| +47% | +$1.02M |
|
67
Quince Therapeutics
QNCX
$86.5M
| $3.12M | 0.33% |
2,947,652
-272,348
| -8% | -$289K |
|
|
EQC
68
DELISTED
Equity Commonwealth
EQC
| $3.12M | 0.32% |
165,261
-134,739
| -45% | -$2.54M |
|
69
Lantheus
LNTH
$3.75B
| $3.11M | 0.32% |
+50,000
| New | +$3.11M |
|
70
Genmab
GMAB
$16.7B
| $2.99M | 0.31% |
+100,000
| New | +$2.99M |
|
71
MindMed
MNMD
$689M
| $2.82M | 0.29% |
+300,000
| New | +$2.82M |
|
|
KNTE
72
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $2.6M | 0.27% |
977,626
-1,624,021
| -62% | -$4.32M |
|
73
Athira Pharma
ATHA
$15.5M
| $2.34M | 0.24% |
852,715
-300,000
| -26% | -$822K |
|
|
ADAP
74
Adaptimmune Therapeutics
ADAP
$13.9M
| $2.28M | 0.24% |
1,443,619
-2,943,619
| -67% | -$4.65M |
|
|
AMRN
75
Amarin Corp
AMRN
$311M
| $2.23M | 0.23% |
125,000
-29,327
| -19% | -$522K |
|